CPA
NAUT icon

Capital Performance Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Capital Performance Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7
Closed -$20 – 1748
2024
Q3 		$20 Buy
+7
New +$18 ﹤0.01% 2855

Other funds holding NAUT

AH Capital Management
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Amazon.com Inc
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Performance Advisors's NAUT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Nautilus Biotechnolgy (NAUT) in Q4 2024, closing a stake of 7 shares — an estimated $20 sold.

Capital Performance Advisors first reported a position in NAUT in Q3 2024 and held it in 1 quarter. The position peaked at $20 in Q3 2024. 88 funds tracked by Wall St. Rank hold NAUT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Nautilus Biotechnolgy position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 7 Nautilus Biotechnolgy shares in Q4 2024, an estimated $20.
  • Capital Performance Advisors first reported a position in Nautilus Biotechnolgy in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Nautilus Biotechnolgy position peaked at $20 in Q3 2024.
  • 88 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.